Navigation Links
Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
Date:4/22/2008

777.6 835.0

Total liabilities and stockholders'

equity $1,310.3 $1,345.1

EDWARDS LIFESCIENCES CORPORATION

Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP financial measures that exclude certain items, such as special charges and gains, results of discontinued products, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided only on a non-GAAP basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, nor superior to, the corresponding measures calculated in accordance with GAAP.

The items described below are excluded from the GAAP financial results in the reconciliations that follow:

Special Charges, net -- The Company incurred certain special charges and gains in 2008 related to the following:

1) Loss on sale of product line: $8.1 million net loss on the sale of the

LifeStent product line in the first quarter of 2008;

2) Lit
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
2. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
3. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
4. Edwards Lifesciences Announces Organizational Changes
5. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
7. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
8. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... SCOTTSDALE, Ariz., Sept. 14 CHS, an inVentiv,Health company ... U.S. Department,of Defense as a recipient of the 2007 ... by the National Committee of Employer,Support of the National ... America,s employers who provide support to their employees,serving in ...
... SOUTH SAN FRANCISCO, Calif., Sept. 14 ,Exelixis, ... the company has,submitted a comprehensive data report relating ... 2007, GSK requested to initiate its review of,XL880 ... the,product development and commercialization agreement between the two,companies. ...
... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ... Lim, MD, Halozyme,s President and Chief Executive Officer,will present ... be held at,the Grand Hyatt Hotel in New York ... (6:00 a.m. Pacific time). Interested parties can access ...
Cached Biology Technology:CHS Receives Prestigious Honor from Department of Defense 2CHS Receives Prestigious Honor from Department of Defense 3Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference 2
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... COLUMBUS, Ohio The wasting disease associated with some ... also cause significant damage to the heart, new research ... muscle wasting and dramatic weight loss, was believed to ... showed that the condition reduces heart function and changes ...
... pathogens that were once thought to be very different ... are not only similar but also suggest that in ... according to a review published this week in the ... used by bacterial and fungal species to promote genetic ...
... The National Institute of General Medical Sciences has awarded ... for a study titled "Expression Genetics in Drug Therapy." The ... and reduce the number of adverse drug reactions among patients ... State as a member of a nationwide Pharmacogenomics Research Network ...
Cached Biology News:Muscle wasting in cancer does not spare the heart 2Muscle wasting in cancer does not spare the heart 3Linking microbial sex and virulence 2$9.1 million grant to improve drug therapy using gene profiles 2$9.1 million grant to improve drug therapy using gene profiles 3
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Synthetic peptide derived from the N-terminal ... 17 open reading frame 37 (C17orf37 protein) ... C35 protein. On Western blots it identifies ... Reactivity: Human (positive control: full-length human ...
... Two separate vials containing 200 ... same sequence used as antigens for ... 160890) To be ... cyclase polyclonal antiserum (Catalog No. 160890) ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: